
    
      To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular
      carcinoma

      To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma
      patients after administration of Oncoxin plus Surafenib

      To see if there is reduction tumor size and or number in hepatocellular carcinoma patients
      after administration of Oncoxin plus Surafenib

      To see if there is improvement of quality of life in hepatocellular carcinoma patients after
      administration of Oncoxin plus Surafenib

      To see if there is improved survival in hepatocellular carcinoma patients after
      administration of Oncoxin plus Surafenib
    
  